ストックスクリーナーアプリを入手
0.962
0.52%
-0.005
アフターアワーズ：
.96
-0.002
-0.21%
前日終値:
$0.967
開ける：
$0.941
24時間の取引高:
21,076
Relative Volume:
0.10
時価総額：
$4.94M
収益：
-
当期純損益:
$-6.78M
株価収益率:
-0.0225
EPS:
-42.6996
ネットキャッシュフロー:
$-4.67M
1週間 パフォーマンス:
-0.31%
1か月 パフォーマンス:
-6.60%
6か月 パフォーマンス:
-26.00%
1年 パフォーマンス:
-15.61%
1日の値動き範囲:
$0.92
$0.9699
1週間の範囲:
$0.92
$0.99
52週間の値動き範囲:
$0.85
$2.30
Clearmind Medicine Inc Stock (CMND) Company Profile
CMND を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
0.962 | 4.96M | 0 | -6.78M | -4.67M | -42.70 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Clearmind Medicine Inc (CMND) 最新ニュース
symbol__ Stock Quote Price and Forecast - CNN
SciSparc-Clearmind Collaboration Leads to Publication of - GlobeNewswire
SciSparc Ltd. Announces European Patent Application for Cocaine Addiction Treatment in Collaboration with Clearmind Medicine Inc. - Nasdaq
Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction - The Manila Times
SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction - The Manila Times
Evolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsight - GlobeNewswire Inc.
Clearmind Medicine files patent for eating disorder treatment - Investing.com
SciSparc and Clearmind file patent for eating disorder treatment - Investing.com
Clearmind Medicine files patent for eating disorder treatment By Investing.com - Investing.com South Africa
SciSparc and Clearmind file patent for eating disorder treatment By Investing.com - Investing.com India
Psychedelic: Clearmind completes clinical site initiations for AUD trial - Yahoo Finance
SciSparc and Clearmind File Patent for Eating Disorder Treatment - TipRanks
Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders - The Manila Times
SciSparc-Clearmind Collaboration Leads to Filing of - GlobeNewswire
Clearmind Medicine Inc. Files International Patent for Novel Treatment of Eating Disorders Using 3-MMC and PEA - Nasdaq
Novel Eating Disorder Treatment Patent Filed for 70M Patient Market | SPRC Stock News - Stock Titan
Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites - The Manila Times
Clearmind Medicine Inc. Initiates Patient Enrollment for Phase I/IIa Clinical Trial in Alcohol Use Disorder - Nasdaq
Clearmind Medicine (NASDAQ:CMND) Stock Price Down 4.8% – Here’s Why - Defense World
Clearmind Medicine Inc (CMND) requires closer examination - uspostnews.com
Clearmind Medicine Inc Inc. (CMND) Price Performance and Its Relation to the Tech Industry - investchronicle.com
Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts - TradingView
Clearmind Medicine to Host Live Webinar 'Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts - The Manila Times
Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading - Bluefield Daily Telegraph
Clearmind Medicine Receives Notice Of Allowance For United States Patent Covering Binge Behavior - marketscreener.com
Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior - TradingView
Clearmind Medicine Launches First U.S. Clinical Site For FDA-Approved Alcohol Use Disorder Trial - Nasdaq
Clearmind Medicine begins phase I/IIa trial for AUD treatment - Investing.com
Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism - The Manila Times
Clearmind Medicine Inc. Initiates Phase I/IIa Clinical Trial for CMND-100 in Alcohol Use Disorder at Johns Hopkins University - Nasdaq
Clearmind Medicine Launches First U.S. Clinical Site For Its FDA-Approved Clinical Trial To Combat Alcoholism - MarketScreener
Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial - Yahoo Finance
Clearmind Medicine (CMND) Launches U.S. Clinical Trial for Alcoh - GuruFocus
Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder - The Manila Times
Clearmind Medicine files patent for new psychedelic compounds - Investing.com
Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders - The Manila Times
Clearmind Medicine stock hits 52-week low at $0.95 By Investing.com - Investing.com South Africa
Clearmind Medicine stock hits 52-week low at $0.95 - Investing.com Australia
Clearmind launches data system for alcohol addiction trial - Investing.com
Clearmind Implements EDC System To Streamline Phase I/II Trial For Alcohol Use Disorder Drug - Nasdaq
Clearmind Medicine launches EDC system to support Phase I/II trial - TipRanks
Clearmind launches data system for alcohol addiction trial By Investing.com - Investing.com Australia
Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment - The Manila Times
Psychedelic Revolution: Inside Clearmind Medicine's Breakthrough - AInvest
Psychedelic: Exclusive talk with biotech company Clearmind Medicine - Yahoo Finance
Clearmind’s AUD drug candidate arrives in the U.S. for trials By Investing.com - Investing.com South Africa
Clearmind Medicine Moves Closer to CMND-100 Trial After Alcohol Use Disorder Drug Candidate Arrives in US - MarketScreener
Clearmind’s AUD drug candidate arrives in the U.S. for trials - Investing.com
Clearmind Medicine's FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones - The Manila Times
Clearmind Medicine Inc. Announces Arrival of CMND-100 in the U.S. Ahead of Phase I/IIa Trial for Alcohol Use Disorder - Nasdaq
Clearmind Medicine Inc (CMND) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
3.74%
大文字化:
|
ボリューム (24 時間):